Table 2.
Protein kinase inhibitors used to probe the oncogenic signaling mechanism of DU-4475.
| Inhibitor | Main Target Kinase | Signaling Pathway |
|---|---|---|
| Alectinib | Alk, Ret | Receptor PTKs |
| BMS-754807 | Insulin receptor, IGF-1R | Receptor PTKs |
| Cabozantinib | Tet, VEGFR | Receptor PTKs |
| Crizotinib | Alk, Ros1, Met | Receptor PTKs |
| Erdafitinib | FGFR | Receptor PTKs |
| Erlotinib | EGFR | Receptor PTKs |
| Lapatinib | EGFR | Receptor PTKs |
| Nintadenib | VEGFR, PDGFR, FGFR | Receptor PTKs |
| Regorafenib | VEGFR | Receptor PTKs |
| Sunitinib | PDGFR, VEGFR | Receptor PTKs |
| MK-2206 | Akt | PI 3-Kinase pathway |
| GSK690693 | Akt | PI 3-kinase pathway |
| Vemurafenib | BRAF | MAP kinase pathway |
| Dabrafenib | BRAF | MAP kinase pathway |
| Trametinib | Mek | MAP kinase pathway |
| Binimetinib | Mek | MAP kinase pathway |
| Bosutinib | Src, Abl | Cytoplasmic PTKs |
| Dasatinib | Src, Abl | Cytoplasmic PTKs |
| Saracatinib | Src, Abl | Cytoplasmic PTKs |
| Nilotinib | Abl | Cytoplasmic PTKs |